Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies.
about
Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancerCurrent Advances in Virus-Like Particles as a Vaccination Approach against HIV InfectionVirus-like particles as antigenic nanomaterials for inducing protective immune responses in the lungIn vivo delivery of antigens by adenovirus dodecahedron induces cellular and humoral immune responses to elicit antitumor immunity.Adeno-associated virus-like particles as new carriers for B-cell vaccines: testing immunogenicity and safety in BALB/c miceInfluenza virus-like particles as an antigen-carrier platform for the ESAT-6 epitope of Mycobacterium tuberculosisAbrogation of contaminating RNA activity in HIV-1 Gag VLPs.Interaction between a 54-kilodalton mammalian cell surface protein and cowpea mosaic virus.Advantages to the use of rodent hepadnavirus core proteins as vaccine platformsVaccine delivery system for tuberculosis based on nano-sized hepatitis B virus core protein particlesA Comparison Study of iTEP Nanoparticle-Based CTL Vaccine Carriers Revealed a Surprise Relationship between the Stability and Efficiency of the Carriers.Virus-like particles: flexible platforms for vaccine development.Th2 polarization in peripheral blood mononuclear cells from human immunodeficiency virus (HIV)-infected subjects, as activated by HIV virus-like particles.Virus-like particle vaccines and adjuvants: the HPV paradigm.Developments in virus-like particle-based vaccines for infectious diseases and cancer.Developments in virus-like particle-based vaccines for HIV.Virus-like particles that display Zika virus envelope protein domain III induce potent neutralizing immune responses in mice.Nasal and pulmonary vaccine delivery using particulate carriers.Short communication: limited induction of IL-10 in PBMCs from HIV-infected subjects treated with HIV-VLPs.Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses.Immune-tolerant elastin-like polypeptides (iTEPs) and their application as CTL vaccine carriersAdjuvant effect of B domain of staphyloccocal protein A displayed on the surface of hepatitis B virus capsid.Coinoculation with hepatitis B surface and core antigen promotes a Th1 immune response to a multiepitopic protein of HIV-1.
P2860
Q24622837-DBE425EB-F89D-41C6-9FC3-EDAE0C0043A5Q26775082-BE4235FA-464A-4508-8C98-375126A1B308Q26825031-348FB873-14FC-4CC9-B07B-B9E5E837A4C5Q33931622-3192976E-EEA4-4AD3-9982-FCE6D158D530Q34440125-F3DC4E83-3F05-42BB-96F3-C8123F175249Q35300720-35A8BD3E-407D-49B3-9D02-4473032BDAE5Q35478282-7BBC4622-05BA-421C-AD63-77027D2D07BEQ35635388-25B8B197-3862-4119-BE80-137F22B4BC1DQ35663329-93DEDA97-5253-47D1-A1E0-C89B0C9ADEA6Q36669184-F08D8C6F-F1F4-44D5-81EF-750759CBF485Q36723754-3968EDEC-3F6B-4A65-BB79-7DB34C5BA765Q36837144-6C116849-A16B-4AD4-A2E6-07C1F48713A6Q37033232-C7B71358-6EFF-4797-8AA1-6CF8B0C3AEE7Q37608311-96D24B0F-85E2-43A3-BFA5-3B5C629310EBQ37951525-9AC2B3DC-B693-497F-99C2-BD95421AD83AQ38081965-CE8508E9-3E2C-44EF-A930-ED59DDC099DEQ38156841-914041BF-A0DC-40E0-8222-9CDD06E9B4F5Q38465267-E2C03DE8-1251-413F-AFDC-6437973B1A35Q38874078-2C64151B-94A5-4955-B9D9-EBDE57F3EC4BQ38879108-3B296232-63D3-4B47-BC02-19D9D1C00013Q39678040-AC5FFF3C-31E8-4D82-88B9-E85F22FCE77EQ41534162-828D0278-B5C8-4857-AAC1-1317CDB4FF4DQ51252316-A34247B3-9214-468C-9F7D-F48794744E45
P2860
Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2005
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Virus-like particles as carrie ...... y carrier-specific antibodies.
@en
Virus-like particles as carrie ...... y carrier-specific antibodies.
@nl
type
label
Virus-like particles as carrie ...... y carrier-specific antibodies.
@en
Virus-like particles as carrie ...... y carrier-specific antibodies.
@nl
prefLabel
Virus-like particles as carrie ...... y carrier-specific antibodies.
@en
Virus-like particles as carrie ...... y carrier-specific antibodies.
@nl
P2093
P2860
P1433
P1476
Virus-like particles as carrie ...... y carrier-specific antibodies.
@en
P2093
Andrea Jegerlehner
Christiane Ruedl
Katrin Schwarz
Martin F Bachmann
Tazio Storni
Vania Manolova
P2860
P304
P356
10.1128/JVI.79.2.717-724.2005
P407
P577
2005-01-01T00:00:00Z